1-20 of 1785 Search Results for

pump

Sort by
Book Chapter
Series: Frontiers in Diabetes
Volume: 24
Published: 17 November 2014
10.1159/000363486
EISBN: 978-3-318-02337-4
..., and thorough patient education. Although obviously more expensive than MDI, CSII may be cost-effective when elevated HbA 1c levels or continued disabling hypoglycemia persist despite optimized MDI therapy. More recently, sensor-augmented pumps (SAPs) have become available. These combine the technology...
Book Chapter
Series: Frontiers in Diabetes
Volume: 24
Published: 17 November 2014
10.1159/000363488
EISBN: 978-3-318-02337-4
... improvement in treatment satisfaction without a substantial change in glycosylated hemoglobin A 1c (HbA 1c ). Elevated levels of HbA 1c not only at the start of CSII, but also during the follow-up, may be an important indicator of pump discontinuation. Sensor-augmented pump therapy (SAP) has a more...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350624
EISBN: 978-3-318-02416-6
... Abstract Omeprazole (OPZ), developed by AB Hässle/Astra (Sweden), and lansoprazole (LPZ), developed by Takeda Chemical Industries Ltd. (Japan), were the world's first and second proton pump inhibitors (PPIs), respectively, approved for clinical use in humans. These PPIs have been widely used...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350626
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. There are genetic differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into four...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350628
EISBN: 978-3-318-02416-6
... Abstract During the last two decades the therapeutic superiority of proton pump inhibitors (PPIs) over other drugs has dramatically changed the management of gastroesophageal reflux disease (GERD). Their important clinical efficiency as compared with previous drugs, especially H 2 -receptor...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350629
EISBN: 978-3-318-02416-6
... and complications. This review will focus on the use of proton pump inhibitors (PPIs) in the prevention and healing of NSAID-induced gastroduodenal lesions. The role of PPIs will be compared with alternative gastroprotective agents and placebo. Gastrointestinal (GI) adverse effects of nonsteroidal anti...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350631
EISBN: 978-3-318-02416-6
... Abstract The combination of a proton pump inhibitor (PPI) with two of the following three antibiotics, amoxicillin, clarithromycin, and metronidazole, has been reported to achieve a high eradication rate. These regimens are accepted as standard regimens worldwide. The rationale of PPI-based...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350632
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are effective in preventing recurrent peptic ulcer bleeding when used in high-dose intravenous infusion or oral form. Intermittent injection or low-dose administration of PPIs may not produce such benefit. These findings are based on meta-analysis...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350633
EISBN: 978-3-318-02416-6
... in individual response to stress exist in the background. Acid is considered to be a factor that modifies the manifestation of FD symptoms. Although it has not been proven that excessive gastric acid is present in FD patients, proton pump inhibitors (PPIs) are widely used as first-line drugs in the treatment...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350635
EISBN: 978-3-318-02416-6
... Abstract Proton-pump inhibitors (PPIs) are some of the most widely used drugs in the world. Although the safety of PPIs is well established, there are several side effects, including some which have only recently been recognized. The side effects include diarrhea and various symptoms due...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350638
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are widely used for maintenance treatment of gastroesophageal reflux diseases as well as prevention of gastroduodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs. Since they are used for long periods concurrently with other drugs...
Book
Book Cover Image
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/isbn.978-3-318-02416-6
EISBN: 978-3-318-02416-6
Book Chapter
Series: Developments in Ophthalmology
Volume: 41
Published: 23 May 2008
10.1159/000131095
EISBN: 978-3-8055-8377-0
... of the patient’s clothes were used, but were oftencomplicated by infection. A new option is the implantable pump dacryoreservoir. Materialand Methods: In 21 patients with a Schirmer test without anaesthesia of <2mm in 5 min, aMedtronic 60-ml reservoir was implanted into a pocket under the subcutaneous tissues...
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Series: Antibiotics and Chemotherapy
Volume: 40
Published: 01 June 1988
10.1159/000415207
EISBN: 978-3-318-03215-4
Book Chapter
Series: Antibiotics and Chemotherapy
Volume: 40
Published: 01 June 1988
10.1159/000415208
EISBN: 978-3-318-03215-4
Book Chapter